• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

    9/8/25 9:30:00 AM ET
    $CCCC
    $CGON
    $HCM
    $IDYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CCCC alert in real time by email

    USA News Group News Commentary

    Issued on behalf of Oncolytics Biotech Inc.

    VANCOUVER, BC, Sept. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development timelines for life-saving cancer treatments[1], while major pharmaceutical companies deployed several multi-billion-dollar strategic partnerhips (with one topping $11 billion) to secure next-generation immunotherapies[2]. These recent designations are creating momentum for companies advancing breakthrough oncology platforms including Oncolytics Biotech Inc. (NASDAQ:ONCY), HUTCHMED (China) Limited (NASDAQ:HCM), CG Oncology, Inc. (NASDAQ:CGON), C4 Therapeutics, Inc. (NASDAQ:CCCC), and IDEAYA Biosciences, Inc. (NASDAQ:IDYA).

    USA News Group logo (PRNewsfoto/USA News Group)

    Industry analysts expect the antibody-drug conjugate market to reach $50 billion by 2030[3], driven by 16 approved therapies and accelerating clinical pipelines. Immuno-oncology revenues jumped from $94 billion to $109.39 billion in 2025 alone[4], as leading institutions recognize the transformative potential of precision-targeted therapies and combination treatment approaches for previously untreatable cancers.

    Oncolytics Biotech Inc. (NASDAQ:ONCY) has announced impressive clinical data in metastatic colorectal cancer that could accelerate the company's path to registration. The latest results show pelareorep achieved a median progression-free survival of 16.6 months compared to just 5.7 months with standard treatments, representing approximately 2.5 times longer disease control in KRAS mutant colorectal cancer patients.

    Even more striking, overall survival reached 27.0 months versus the typical 11.2 months, representing a dramatic improvement in one of oncology's most challenging areas. This data comes from the REO 022 trial testing pelareorep with FOLFIRI and bevacizumab in second-line treatment.

    "These studies validate pelareorep's mechanism of action and present a clear opportunity to accelerate the pursuit of a registration-enabled study in the underserved KRAS mutant subset of mCRC patients," said Jared Kelly, CEO of Oncolytics. "Given pelareorep's activity in this difficult-to-treat cancer and other RAS-mutated gastrointestinal ("GI") tumors, including metastatic pancreatic and anal cancers, we believe pelareorep is positioned to become the premier platform immunotherapy in the GI space."

    The company plans to work with regulators to define a path toward registration in KRAS mutant colorectal cancer.

    The results extend beyond survival numbers. Translational studies confirmed pelareorep actually replicates inside tumor cells while activating immune responses, including dendritic cell maturation and CD8+ T cell activation. This proves the drug's ability to transform "cold" tumors into "hot" targets responsive to immunotherapeutic treatments.

    Pelareorep represents a systemically delivered oncolytic virus that reprograms the immune system against cancer. Unlike traditional chemotherapy that attacks cells indiscriminately, this immunotherapy selectively targets cancer while mobilizing the body's natural defenses.

    The company is simultaneously advancing toward registration-enabling trials in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), where survival data proved equally compelling. Clinical results showed a 21.9% two-year overall survival rate compared to the 9.2% historical benchmark for standard chemotherapy protocols.

    Importantly, pelareorep demonstrated a 62% objective response rate when combined with chemotherapy and checkpoint inhibitors. This matters because checkpoint inhibitors currently lack approval for pancreatic cancer, suggesting pelareorep may unlock immunotherapy effectiveness in historically resistant tumors.

    Oncolytics recently provided updated safety data for pelareorep, which has been administered to over 1,200 patients across multiple studies. The most common side effects remain mild flu-like symptoms, with data showing pelareorep doesn't modify the safety profile of established chemotherapy regimens.

    The company confirmed ongoing discussions with the U.S. Food and Drug Administration (FDA) to finalize pivotal study parameters for pancreatic cancer, targeting potential trial initiation activities by Q4 2025. Pelareorep holds both Fast Track and Orphan Drug designations from the FDA for pancreatic cancer, facilitating expedited review processes.

    Recent leadership changes reflect an execution-focused approach. CEO Jared Kelly and Chief Business Officer Andrew Aromando both contributed to Ambrx Biopharma's US$2 billion acquisition by Johnson & Johnson. Oncolytics eliminated its At-the-Market and Equity Line financing facilities, suggesting confidence in current cash resources to reach key development milestones.

    With survival benefits approaching 3× standard care in colorectal cancer and regulatory discussions advancing for pancreatic cancer trials by Q4 2025, Oncolytics appears positioned at a critical inflection point where proof-of-concept has evolved into potential registration-enabling studies. The company's dual-track approach in gastrointestinal cancers, combined with an experienced leadership team and FDA Fast Track designation, suggests pelareorep may soon transition from clinical promise to commercial reality.

    CONTINUED… Read this and more news for Oncolytics Biotech at:  https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ 

    In other recent industry developments and happenings in the market include:

    HUTCHMED (China) Limited (NASDAQ:HCM) highlighted clinical data from multiple oncology studies at the 2025 World Conference on Lung Cancer and CSCO Annual Meeting, showcasing updated analysis from savolitinib's SACHI, SAVANNAH and Phase IIIb confirmatory studies in non-small cell lung cancer patients.

    The company will present first-time clinical data of HMPL-653, a novel CSF-1R inhibitor, from a Phase I study in patients with tenosynovial giant cell tumor. Savolitinib, an oral and highly selective MET tyrosine kinase inhibitor being jointly developed with AstraZeneca, continues advancing through multiple clinical programs targeting various lung cancer indications.

    According to Hutchmed's announcement, updated analysis from savolitinib's SACHI, SAVANNAH and a Phase IIIb confirmatory study in non-small cell lung cancer patients will be presented at WCLC 2025.

    The comprehensive clinical program spans investigator-initiated studies of fruquintinib and surufatinib across multiple cancer types, with HUTCHMED positioning itself as an innovative commercial-stage biopharmaceutical company committed to bringing targeted therapies from in-house discovery to patients worldwide. The company has successfully marketed its first three medicines in China, with its lead compound also approved globally, including in the US, Europe and Japan.

    CG Oncology, Inc. (NASDAQ:CGON) continues to demonstrate best-in-disease durability with its cretostimogene immunotherapy, reporting an additional 12 patients achieving complete response at 24 months in the BOND-003 Cohort C study. The robust 24-month complete response rate of 41.8% observed in 46 out of 110 patients with high-risk non-muscle invasive bladder cancer unresponsive to BCG treatment represents unprecedented durability in this heavily pretreated patient population. Notably, 90% of 12-month responders remained disease-free at 24 months, while 96.6% of patients were free from progression to muscle-invasive disease at 24 months.

    "Based on the latest data cut, I remain very encouraged that if approved, cretostimogene will represent an important, bladder-sparing advancement in the management of high risk non-muscle invasive bladder cancer in patients who have disease that is unresponsive to BCG," said Trinity J. Bivalacqua, MD, PhD, Urologic Oncology at Penn Medicine and Co-Director, Genitourinary Cancer Service Line, Abramson Cancer Center. "In my clinical experience, bladder cancer patients are seeking treatment options that offer durable and sustained results."

    The company is preparing to initiate its BLA submission for cretostimogene in the fourth quarter of 2025, with the Phase 3 BOND-003 Cohort C representing the largest study in this patient population to date. Cretostimogene's safety profile remains consistent with no Grade 3 or greater treatment-related adverse events or deaths reported, supporting its potential as a breakthrough backbone treatment for bladder cancer patients.

    C4 Therapeutics, Inc. (NASDAQ:CCCC) completed enrollment and dose escalation for its Phase 1 trial of cemsidomide in multiple myeloma, with the investigational MonoDAC degrader continuing to demonstrate a well-tolerated safety profile and compelling response rates. The company will present comprehensive data from all safety and efficacy evaluable multiple myeloma patients across all dose levels studied in the cemsidomide with dexamethasone cohort at the International Myeloma Society Annual Meeting on September 20, 2025. Cemsidomide is designed as a more potent and selective degrader of IKZF1/3 transcription factors that drive multiple myeloma and non-Hodgkin's lymphomas, with unique pharmacokinetic properties and demonstrated anti-myeloma activity and immunomodulatory effects.

    C4 Therapeutics will host an investor webcast on September 20, 2025, at 3 PM ET to highlight the data presentation and provide additional detail on the planned next steps of clinical development. The company is progressing its TORPEDO platform to efficiently design and optimize small-molecule degrader medicines targeting difficult-to-treat diseases, with cemsidomide representing a key advancement in harnessing the body's natural protein recycling system.

    IDEAYA Biosciences, Inc. (NASDAQ:IDYA) enrolled their first patient with non-small cell lung cancer in the ongoing Phase 1/2 combination trial of IDE397 and Trodelvy® in patients with MTAP-deletion solid tumors, expanding beyond the initial focus on MTAP-deletion urothelial cancer. IDE397, a potential first-in-class small molecule MAT2a inhibitor, is being combined with Gilead's Trop2-directed antibody-drug conjugate Trodelvy under a clinical study collaboration and supply agreement. MTAP-deletion is found in up to 20% of non-small cell lung cancer cases and represents an area with no approved targeted therapies, creating a significant opportunity for this novel therapeutic approach.

    "We are encouraged by the preliminary expansion data from our Phase 1/2 combination trial with IDE397 and Trodelvy in MTAP-deleted bladder cancer and excited to have dosed the first patient in the non-small cell lung cancer cohort," said Darrin Beaupre, Chief Medical Officer of IDEAYA Biosciences. "This marks an important step in our broader clinical strategy to evaluate the combination across multiple solid tumors with MTAP-deletion."

    IDEAYA retains commercial rights to IDE397 while Gilead provides Trodelvy supply, with the precision medicine oncology company building a deep pipeline focused on synthetic lethality and antibody-drug conjugates for molecularly defined solid tumor indications. The expansion into NSCLC represents a significant milestone in the company's mission to develop tailored, potentially first-in-class targeted therapies aligned to genetic drivers of disease.

    Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ 

    CONTACT:

    USA NEWS GROUP

    [email protected]

    (604) 265-2873

    DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

    While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    SOURCES CITED:

    1. https://www.targetedonc.com/view/a-month-of-breakthroughs-the-fda-s-oncology-decisions-in-august-2025 
    2. https://www.labiotech.eu/best-biotech/oncology-deals-2025/ 
    3. https://www.biospace.com/press-releases/global-cancer-antibody-drug-conjugates-market-us-50-billion-opportunity-by-2030 
    4. https://www.biospace.com/press-releases/oncology-drug-discovery-market-2025-trends-and-key-players 
    5. https://www.biospace.com/press-releases/global-cancer-antibody-drug-conjugates-market-us-50-billion-opportunity-by-2030

    Logo - https://mma.prnewswire.com/media/2603685/5496989/USA_News_Group_Logo.jpg

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/breakthrough-therapy-designations-surge-as-50b-cancer-drug-partnerships-reshape-market-302549075.html

    SOURCE USA News Group

    Get the next $CCCC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCCC
    $CGON
    $HCM
    $IDYA

    CompanyDatePrice TargetRatingAnalyst
    IDEAYA Biosciences Inc.
    $IDYA
    9/4/2025$40.00Overweight
    Barclays
    IDEAYA Biosciences Inc.
    $IDYA
    9/4/2025$41.00Mkt Outperform
    Citizens JMP
    C4 Therapeutics Inc.
    $CCCC
    9/4/2025$8.00Buy
    Guggenheim
    CG Oncology Inc.
    $CGON
    8/19/2025$55.00Overweight
    Piper Sandler
    Oncolytics Biotech Inc.
    $ONCY
    8/13/2025$7.00Buy
    Lake Street
    IDEAYA Biosciences Inc.
    $IDYA
    7/22/2025Buy
    TD Cowen
    IDEAYA Biosciences Inc.
    $IDYA
    7/10/2025$25.00Neutral
    Goldman
    CG Oncology Inc.
    $CGON
    7/10/2025$40.00Buy
    Goldman
    More analyst ratings

    $CCCC
    $CGON
    $HCM
    $IDYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on IDEAYA Biosciences with a new price target

    Barclays initiated coverage of IDEAYA Biosciences with a rating of Overweight and set a new price target of $40.00

    9/4/25 9:01:02 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on IDEAYA Biosciences with a new price target

    Citizens JMP initiated coverage of IDEAYA Biosciences with a rating of Mkt Outperform and set a new price target of $41.00

    9/4/25 9:00:51 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on C4 Therapeutics with a new price target

    Guggenheim initiated coverage of C4 Therapeutics with a rating of Buy and set a new price target of $8.00

    9/4/25 9:00:20 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    $CGON
    $HCM
    $IDYA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development timelines for life-saving cancer treatments[1], while major pharmaceutical companies deployed several multi-billion-dollar strategic partnerhips (with one topping $11 billion) to secure next-generation immunotherapies[2]. These recent designations are creating momentum for companies advancing breakthrough oncology platforms including Oncolytics Biotech Inc. (NASDAQ:ONCY), HUTCHMED (China) Limited (NASDAQ:HCM), CG Oncology, Inc. (NASDAQ

    9/8/25 9:30:00 AM ET
    $CCCC
    $CGON
    $HCM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

    Overall response rate (ORR) of 57% (4/7; 3cPR+1uPR) in patients treated with a combination of 30 mg IDE397 plus 7.5mg/kg Trodelvy® (Dose level 2); ORR of 33% (3/9; 3cPR) at 15 mg IDE397 plus 10mg/kg Trodelvy® (Dose level 1)Manageable safety profile at both expansion doses, consistent with known adverse events observed with each agent alone, with no treatment related serious adverse events observed at the IDE397 30mg and Trodelvy® 7.5 mg/kg expansion doseSelection of recommended Phase 2 dose is targeted by end of 2025, with next update planned for a medical conference in H1 2026  SOUTH SAN FRANCISCO, Calif., Sept. 8, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading preci

    9/8/25 8:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

    In KRAS mutant 2L mCRC, pelareorep delivers prolonged survival benefit with a median PFS and median OS approximately 2.5x the current standard of care Translational data from multiple studies confirm pelareorep replication in CRC tumors and immune activation Company to define regulatory pathway and advance potential IST in KRAS mutant CRC patient population SAN DIEGO, Sept. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today highlighted clinical and translational data from three metastatic colorectal cancer ("mCRC") studies demonstrating consistent efficacy signals, immune activati

    9/8/25 7:00:00 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CCCC
    $CGON
    $HCM
    $IDYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CCCC
    $CGON
    $HCM
    $IDYA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CCCC
    $CGON
    $HCM
    $IDYA
    SEC Filings

    View All

    Director Mulay James exercised 27,015 shares at a strike of $0.60 and sold $851,797 worth of shares (27,015 units at $31.53) (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/8/25 4:16:22 PM ET
    $CGON

    Director Song Hong Fang sold $2,779,542 worth of shares (100,000 units at $27.80) (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/4/25 5:00:07 PM ET
    $CGON

    Director Post Leonard E sold $28,000 worth of shares (1,000 units at $28.00) and exercised 1,000 shares at a strike of $0.60 (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/4/25 4:30:05 PM ET
    $CGON

    Decheng Capital Global Life Sciences Fund Iv, L.P. bought $7,600,000 worth of shares (400,000 units at $19.00) (SEC Form 4) (Amendment)

    4/A - CG Oncology, Inc. (0001991792) (Issuer)

    4/9/24 7:08:23 PM ET
    $CGON

    SEC Form 6-K filed by Oncolytics Biotech Inc.

    6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

    9/8/25 7:30:25 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by IDEAYA Biosciences Inc.

    8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)

    9/8/25 6:08:13 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by CG Oncology Inc.

    144 - CG Oncology, Inc. (0001991792) (Subject)

    9/5/25 4:24:48 PM ET
    $CGON

    $CCCC
    $CGON
    $HCM
    $IDYA
    Financials

    Live finance-specific insights

    View All

    Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

    Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions Translational data further elucidate pelareorep's mechanism of action and ability to prime the tumor microenvironment for treatment Commitment to limiting dilution evidenced by termination of At-the-Market and Equity Line of Credit facilities SAN DIEGO, Aug. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareo

    8/8/25 9:05:00 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

    American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers Poster on pelareorep's stimulation of adaptive and innate immunity to be shared at ASCO Annual Meeting Conference call and webcast today at 4:30 p.m. ET to discuss Q1 results and clinical outlook SAN DIEGO, Calif. and CALGARY, AB, May 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for the first qu

    5/14/25 4:01:00 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

    Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter of 2025. Conference Call & Webcast Date: Wednesday, May 14, 2025Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – Interna

    5/6/25 7:00:00 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CCCC
    $CGON
    $HCM
    $IDYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

    SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 7:53:04 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by C4 Therapeutics Inc.

    SC 13G - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 6:43:36 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

    SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

    11/14/24 4:23:02 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CCCC
    $CGON
    $HCM
    $IDYA
    Leadership Updates

    Live Leadership Updates

    View All

    C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

    WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, Canada. IMS Annual Meeting 2025 Oral PresentationTitle: Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaPresen

    9/3/25 7:00:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HUTCHMED Announces Appointment of Acting Chief Executive Officer

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executive Director and Chief Financial Officer of the Company, as Acting Chief Executive Officer with immediate effect, in addition to his role as Chief Financial Officer. Dr Dan Eldar, Chairman and Non-executive Director, said, "The Board expresses its full support for Dr Su and wishes him a speedy recover

    8/24/25 8:20:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

    Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

    7/8/25 10:25:00 AM ET
    $CELC
    $CTOR
    $EXEL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)